[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stem-cells\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stem-cells":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,73,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100642907","phase-1-repeated-injections-of-adipose-derived-stem-cells-in-rotator-cuff-tears-100642907",false,"NCT07592936","Repeated Injections of Adipose-derived Stem Cells in Rotator Cuff Tears","Effects and Benefits of Repeated Injections of Adipose-derived Stem Cells on Shoulder Function in Rotator Cuff Tears: A Randomized Controlled Study","Inclusion Criteria:\n\n* Clinical signs and symptoms compatible with a traumatic RCT\n* MR verified supraspinatus tear\n* Reparable lesion with tendon retraction \\\u003C 2 cm.\n* Fatty infiltration level 0-2 according to Fuchs or out of 5 based on Goutalliers classification\n* No history of inflammatory disease\n* Negative infectious disease marker tests Signed consent to the study\n\nExclusion Criteria:\n\n* Former surgery in the affected shoulder\n* Signs of infection\n* Immunosuppression (due to clinical condition or medical therapy)\n* Any malignancy within 5 years prior to screening\n* Previous radiotherapy to the shoulder\n* BMI under 18\n* BMI above 35\n* Allergy to antibiotics such as penicillin\n* Coagulopathy","ALL","30 Years","69 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","The aim of the project is to investigate whether repeated implantations of micro-fragmented adipose tissue (MFAT), into the shoulder muscle can improve the outcome of standard surgical treatment for rotator cuff tears (RCT). The investigators hypothesize that combining surgery with repeated implantations of micro-fragmented adipose tissue (MFAT) into the muscle provides a more effective treatment for patients with rotator cuff tears compared to standard surgical treatment. The result would be better outcomes such as improved shoulder functioning and reduced pain.",[28,29,30],"Rotator Cuff Tears","Rotator Cuff Injuries","Stem Cells",[32,33],"Adipose derived stem cells","ADSC","NOT_YET_RECRUITING","2026-06-09",{"date":37,"type":38},"2026-06-12","ACTUAL",{"date":40,"type":21},"2026-08",{"date":42,"type":21},"2028-08",{"name":44,"class":45},"University of Southern Denmark","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100589181","phase-2-insulin-producing-stem-cell-transplantation-clinical-trial-in-type-1-diabetes-100589181","NCT06951074","Insulin Producing Stem Cell Transplantation Clinical Trial in Type 1 Diabetes","Autologous Insulin Producing Mesenchymal Stem Cell Transplantation in Youth With Type 1 Diabetes","Inclusion Criteria:\n\n* Type 1 diabetes\n\nExclusion Criteria:\n\n* patients with other autoimmune diseases\n* patients with micro or macro vascular complications\n* patients with other chronic diseases","15 Years","18 Years",{"count":56,"type":21},20,[25,58],"PHASE3","Type 1 Diabetes is a chronic autoimmune disease. It results from autoimmune destruction of pancreatic Beta cells leading to absolute insulin insufficiency. The establishment of pluripotent like human stem cells derived from adipose tissue derived mesenchymal cell origin have introduced a new potential source for cell therapy in type 1 diabetic patients, especially in light of recent successes in producing glucose-sensitive insulin secreting cells and this will be the scope of this study. In the last decade, human clinical trials of introducing insulin producing stem cells from various origins were approved and conducted.",[30,61],"Type 1 Diabetes","RECRUITING","2025-04-26",{"date":65,"type":38},"2025-04-30",{"date":67,"type":38},"2025-04-01",{"date":69,"type":21},"2026-09-01",{"name":71,"class":45},"Ain Shams University",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":85,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":94,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":104,"leadSponsor":106,"locationsCount":72},"100580747","fertility-enhancement-through-regenerative-treatment-in-ovaries-and-testes-100580747","NCT06841328","Fertility Enhancement Through Regenerative Treatment in Ovaries and Testes","Fertility Enhancement Through Regenerative Treatment in Ovaries and Testes: (FERTILE): Prospective Observational Study Evaluating Safety and Efficacy","FERTILE","Male patients:\n\n* Male patients aged 20 to 50 years.\n* Diagnosed with testicular failure (low testosterone) or hypogonadism (impaired gonadal function), or azoospermia (no sperm in ejaculate)\n* Suboptimal response to conventional treatments, such as testosterone replacement therapy (TRT) or fertility-enhancing medications (Clomiphene citrate or anastrozole).\n* General good health without significant contraindications to stem cell or stem cell-derived exosome therapy.\n* Willing and able to provide informed consent and comply with the study protocol.\n* Patients who have been evaluated for testicular failure and are seeking further treatment.\n\nFemale patients:\n\n* Female patients aged 20 to 50 years.\n* Diagnosed with premature ovarian failure (POF) or ovarian insufficiency, confirmed through clinical, hormonal, and imaging assessments.\n* Failure or suboptimal response to conventional treatments, such as hormone therapy.\n* General good health without significant contraindications to stem cell or stem cell-derived exosome therapy.\n* Willing and able to provide informed consent and comply with the study protocol.\n* Patients who have been evaluated for ovarian failure are seeking further treatment.\n\nExclusion criteria\n\n* Severe comorbid conditions, such as advanced cardiovascular disease, renal failure, or uncontrolled diabetes.\n* Active malignancies or history of cancer within the past 5 years.\n* Active infections or systemic inflammatory conditions.\n* History of testicular surgery or trauma that could interfere with the study outcomes.\n* Use of anticoagulants or medications that may contraindicate stem cell or stem cell-derived exosome therapy.\n* Participation in another investigational drug or treatment study within the past 6 months.\n* Contraindications to stem cell or stem cell-derived exosome therapy, such as immune deficiencies or allergies to any treatment components.\n* Severe neurological disorders or cognitive impairment may limit the ability to provide informed consent or follow study instructions.\n* Any condition that, in the investigator's opinion, could interfere with the study or pose an undue risk to the patient.\n* Women with a primary diagnosis of psychogenic ovarian dysfunction or infertility.\n* History of ovarian surgery or trauma that could interfere with the study outcomes.","20 Years","50 Years",{"count":84,"type":21},60,"12 Months","OBSERVATIONAL","This study investigates the safety and efficacy of stem cell or stem cell-derived exosome therapy for gonadal failure, including testicular failure, hypogonadism, ovarian insufficiency, and premature ovarian failure (POF). Conducted at First IVF Clinic, Dubai, it will include 60 participants (30 males, 30 females) aged 20-50 years who have not responded to conventional treatments such as HRT, TRT, or ART.\n\nParticipants will receive intra-gonadal (testicular or ovarian) injections of stem cells or exosomes, with follow-ups at 3, 6, 9, and 12 months to monitor hormonal changes, gonadal function, and potential adverse effects. The study aims to determine whether regenerative therapy can restore hormone production, enhance reproductive function, and regenerate gonadal tissue, providing a novel, culturally appropriate fertility treatment in the UAE, where donor sperm and eggs are not permitted.\n\nBy bridging the gap between preclinical research and clinical application, this study could offer new hope to individuals with gonadal failure, advancing the field of regenerative reproductive medicine.",[89,90,91,92,30,93],"Gonadal Dysfunction","Gonadal Failure","Azoospermia","Testosterone Deficiency","Hypogonadism, Male",[95,96,97,98,99],"Premature Ovarian Failure","Testicular Failure","low testosterone","Stem cell therapy","Exosomes","2025-04-08",{"date":102,"type":38},"2025-04-10",{"date":100,"type":38},{"date":105,"type":21},"2028-04-30",{"name":107,"class":45},"Jumeirah American Clinic",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":117,"conditions":118,"keywords":122,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":72},"100439143","impact-of-obesity-chronic-kidney-disease-and-type-2-diabetes-on-human-urinary-stem-cells-100439143","NCT04998461","Impact of Obesity, Chronic Kidney Disease and Type 2 Diabetes on Human Urinary Stem Cells","URISTEM","Inclusion Criteria - For all participants :\n\n* Age between 18 and 60\n* Non diabetic (fasting blood glucose \\\u003C1.26 g\u002FL)\n* Patient not having objected to participating in the research\n\nInclusion Criteria - For the obese group with normal renal function\n\n* eDFG ≥ 60 ml\u002Fmin\u002F1.73 m2\n* BMI \\> 30 kg\u002Fm2\n* Microalbuminuria \u002F creatinuria ≤ 3mg \u002F mmol and \u002F or proteinuria \\\u003C 0.15 g\u002F24h\n\nInclusion Criteria - For the obese group with impaired renal function\n\n* eDFG \\\u003C 60 ml\u002Fmin\u002F1.73 m2\n* BMI \\> 30 kg\u002Fm2\n* Microalbuminuria \u002F creatinuria ≤ 3mg \u002F mmol and \u002F or proteinuria \\\u003C 0.15 g\u002F24h\n\nInclusion Criteria - For the non-obese group with impaired renal function\n\n* eDFG \\\u003C 60 ml\u002Fmin\u002F1.73 m2\n* BMI between 18 and 30 kg\u002Fm2\n* Microalbuminuria \u002F creatinuria ≤ 3mg \u002F mmol and \u002F or proteinuria \\\u003C 0.15 g\u002F24h\n\nInclusion Criteria - For the non-obese group with normal renal function (control group)\n\n* eDFG ≥ 60 ml\u002Fmin\u002F1.73 m2\n* BMI between 18 and 30 kg\u002Fm2\n* Microalbuminuria \u002F creatinuria ≤ 3mg \u002F mmol and \u002F or proteinuria \\\u003C 0.15 g\u002F24h\n\nExclusion Criteria - For all participants :\n\n* Acute renal failure within 3 months (defined as an increase of more than 50% in usual creatinemia)\n* Inflammatory, infectious, cardiovascular or progressive neoplastic disease\n* Urinary pathology (malformation, infection, etc.)\n* Exclusion period of a previous study or already participating in a clinical research protocol having an impact on the judgment criteria of the study","60 Years",{"count":84,"type":21},"Obesity is at risk for the development of chronic kidney disease but the involved mechanisms are not known (Navarro et al. 2015). Establishing the link between obesity and kidney damage is difficult. Indeed, kidney function measurement lacks precision in obese people (Lemoine et al. 2014) and requires expensive methods such as measurement of 99mTc-DTPA clearance. Biopsies are too invasive for the detection of emerging kidney damage or for the following of the kidney function. Therefore new tools are required for the early identification of at risk individuals for the kidney damage complication.\n\nMesenchymal stem cells may represent such a relevant tool. These cells are present in a large number of organs, including kidney (Costa et al. 2020).\n\nIn addition to be differentiated cells progenitors (Dominici et al. 2006), they also support immunosuppressive, anti-fibrotic and pro-angiogenic functions that have been used for the treatment of kidney fibrosis (Usunier et al. 2014). Therefore, mesenchymal stem cells contribute to tissue homeostasis and their alterations may reflect organ dysfunctions. Indeed, mesenchymal stem cells from obese adipose tissue lose their immunosuppressive (Serena et al. 2016) and differentiation (Gustafson et al. 2009) functions and contribute to fibrosis (Keophiphath et al. 2009) and inflammation (Lee et al. 2010; Gustafson, Nerstedt, et Smith 2019). It is thus probable that kidney dysfunctions are associated with functional alterations of kidney mesenchymal stem cells.\n\nThe collection of mesenchymal stem cells from kidney can easily be performed from urine and next cultivated for amplification. They are called urine stem cells (USC).\n\nFrom our experience with obese mouse adipose stem cells, we observed that functional changes of stem cells preceded adipose tissue dysfunctions. Functional signatures of mesenchymal stem cells are thus representative of changes occuring in the function of the tissue notably in answer to obesity. These features could be used to identify obese people presenting ongoing alterations of kidney function, before clinical manifestations of kidney dysfunction. Because kidney mesenchymal stem cells are easy to isolate from urine, their collection is compatible with the follow up of patients and can be applied to a large number of individuals, including the younger. USC could represent a valuable tool to detect progression towards kidney damage.\n\nIn this project we plan to analyse USC alterations induced by obesity and to identify signatures associated with the progression towards kidney damage and type 2 diabetes. The goal is to evaluate USC as potential marker for the non invasive monitoring of patients in answer to a need that is not achieved by the present available approaches.",[119,120,30,121],"Chronic Kidney Diseases","Obesity","Diabetes type2",[123,119,120,121],"bio-marker","2021-08-02",{"date":126,"type":38},"2021-08-10",{"date":128,"type":21},"2021-11",{"date":130,"type":21},"2026-06",{"name":132,"class":45},"Hospices Civils de Lyon"]